Enhancing muscle healing using platelet-rich plasma (PRP) injection

Platelet-rich plasma (PRP) injection for the treatment of grade 2 muscle injury: a randomised single-blinded clinical trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN66528592

Enrollment

Registered

2011-08-25

Start date

2011-11-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Muscle injury Musculoskeletal Diseases Muscle strain

Interventions

Eligible injured athletes were randomised using computer block randomisation software into two groups: 1. Control group (C) 2. PRP group (PRP) Control group Participants in the control group will r

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. 18 years old and above 2. Acute muscle injury (less than 1 week) 3. Able to understand study protocol and informed consent

Exclusion criteria

Exclusion criteria: 1. Received any form of injection therapy 2. Using non-steroidal anti-inflammatory drugs (NSAIDs) within 1 week prior to randomisation 3. Unable to fulfill follow-up schedule 4. Significant cardiovascular, renal, hepatic disease, malignancy, history of anemia or previous muscle surgery

Design outcomes

Primary

Measure	Time frame
1. Duration to full recovery (return-to-play) Criteria for RTP: 1.1. Muscle strength: at or near pre-injury levels or symmetrical with unaffected site 1.2. Range of motion: at or near pre-injury levels or symmetrical with unaffected site 1.3. Tenderness: injury site should be non-tender 1.4. Inflammation or swelling: no swelling or inflammation Outcomes are measured on a weekly basis until full recovery of the end of week 16	—

Measure

Time frame

1. Duration to full recovery (return-to-play) Criteria for RTP: 1.1. Muscle strength: at or near pre-injury levels or symmetrical with unaffected site 1.2. Range of motion: at or near pre-injury levels or symmetrical with unaffected site 1.3. Tenderness: injury site should be non-tender 1.4. Inflammation or swelling: no swelling or inflammation Outcomes are measured on a weekly basis until full recovery of the end of week 16

—

Secondary

Measure	Time frame
1. Level of platelets - blood and PRP 2. Level of growth factors in PRP 2.1. Insulin-like growth factor (IGF-1) 2.2. Transforming growth factor (TGF)-beta 2.3. Basic fibroblast growth factor (FGF) 2.4. Platelet-derived growth factor (PDGF) 3. Isokinetic muscle strength 4. Brief pain inventory - Short form (BPI-SF) Outcomes are measured on a weekly basis until full recovery of the end of week 16	—

Countries

Malaysia

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026